Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Curve Therapeutics

- PMLiVE

MSD receives NICE recommendation for Keytruda in advanced endometrial cancer

More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK

- PMLiVE

Merck unveils $3bn cost-cutting plan to support pipeline and new product launches

A new restructuring programme has been approved to support the initiative

- PMLiVE

MSD receives MHRA approval for adult-specific pneumococcal vaccine Capvaxive

Illnesses caused by Streptococcus pneumoniae are currently considered a major public health problem by WHO

- PMLiVE

Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn

Cardiovascular diseases result in an estimated 17.9 million global deaths each year

Generative AI platforms drive drug discovery dealmaking

AI-Driven Platforms Enhance Drug Discovery Collaborations

Generative AI platforms are revolutionizing drug discovery, driving significant biopharma dealmaking by enabling the design of innovative small-molecule and biologic drug candidates.

Springer Nature

- PMLiVE

MSD’s Welireg recommended by NICE to treat rare von Hippel-Lindau disease

Approximately one in every 70,000 people are affected by the tumour-causing genetic disease

- PMLiVE

MIT researchers develop new algorithmic framework to identify molecules for drug discovery

SPARROW balances time and cost when optimising molecular candidates to streamline

- PMLiVE

GSK enhances oligonucleotide capabilities with $50m Elsie acquisition

The ability of oligonucleotides to modulate gene expression makes them an attractive modality for drugmakers

- PMLiVE

AI drug discovery biotech Xaira Therapeutics launches with over $1bn in committed funding

The company combines machine learning, data generation and therapeutic product development

- PMLiVE

Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership

The collaboration will see Boehringer use an IBM-developed AI model to boost its drug discovery efforts

- PMLiVE

ICR and Merck renew strategic alliance for development of new cancer drugs

The latest agreement builds on 20 years of collaboration between the two partners

- PMLiVE

ICR researchers develop new test to help identify future cancer treatments

The RKD2 test could make the early stages of drug discovery for cancer more efficient

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links